<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646488</url>
  </required_header>
  <id_info>
    <org_study_id>14-02042</org_study_id>
    <nct_id>NCT02646488</nct_id>
  </id_info>
  <brief_title>Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease</brief_title>
  <official_title>Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effectiveness of practice facilitation
      as a quality improvement strategy for implementing the Million Hearts' ABCS treatment
      guidelines for reducing cardiovascular disease (CVD) among high-risk patients who receive
      care in primary care practices in New York City. The ABCS refer to the following: Aspirin in
      high-risk individuals (A), Blood pressure control and management (B), Cholesterol management
      (C), and Smoking cessation (S). The long-term goal is to create a robust infrastructure to
      disseminate and implement evidence based practice guidelines (EBPG) findings in primary care
      practices and improve practices' capacity to receive and implement other EBPG findings in the
      future.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with documented use of aspirin or other antithrombotic.</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who had a fasting lipoprotein (LDL) test performed and whose risk-stratified fasting LDL is at or below the recommended low density lipoprotein (LDL) goal</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the percentage of patients who had a low density lipoprotein (LDL) test who are prescribed a recommended dose of statin based on risk status if indicated.</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who were screened about tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user.</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients aged 18 through 85 years of age who had a diagnosis of hypertension (HTN) who are prescribed recommended medications, if indicated.</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Cluster 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cluster 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Million Hearts ABCS 6 Months</intervention_name>
    <description>The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).</description>
    <arm_group_label>Cluster 1</arm_group_label>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
    <other_name>Chronic Care Model</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Million Hearts ABCS 9 Months</intervention_name>
    <description>The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).</description>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Million Hearts ABCS 12 Months</intervention_name>
    <description>The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).</description>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Million Hearts ABCS 15 Months</intervention_name>
    <description>The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).</description>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 9 Months</intervention_name>
    <arm_group_label>Cluster 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 12 Months</intervention_name>
    <arm_group_label>Cluster 1</arm_group_label>
    <arm_group_label>Cluster 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 15 Months</intervention_name>
    <arm_group_label>Cluster 1</arm_group_label>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_label>Cluster 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 18 Months</intervention_name>
    <arm_group_label>Cluster 1</arm_group_label>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 21 Months</intervention_name>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 24 Months</intervention_name>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care Regimen 27 Months</intervention_name>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Follow Up Post Intervention 21 Months</intervention_name>
    <arm_group_label>Cluster 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Follow Up Post Intervention 24 Months</intervention_name>
    <arm_group_label>Cluster 1</arm_group_label>
    <arm_group_label>Cluster 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Follow Up Post Intervention 27 Months</intervention_name>
    <arm_group_label>Cluster 2</arm_group_label>
    <arm_group_label>Cluster 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Follow Up Post Intervention 30 Months</intervention_name>
    <arm_group_label>Cluster 3</arm_group_label>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Follow Up Post Intervention 33 Months</intervention_name>
    <arm_group_label>Cluster 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Provider and staff eligibility inclusion criteria.

          -  Eligibility includes working full or part time at the study site.

        Stakeholder eligibility inclusion criteria.

          -  Steering committee members or other key stakeholder from the following groups: Health
             Plan Chief Medical Officer, State health officials in the Chronic Disease Program, and
             leadership from relevant national associations (American Heart Association), members
             of Advisory Board of CHCANYS (these are physician leaders).

        Patient eligibility inclusion criteria:

          -  at least one of the ABCS risk factors for CVD (i.e., hypertension, hyperlipidemia,
             eligible for aspirin and/or is a current smoker)

          -  must have received care at the clinic for at least 12 months

          -  Patients eligible for aspirin are those with a documented ICD-9 code for ischemic
             vascular disease in the last 12 months. Similarly, patients with a diagnosis of
             hypertension and/or hyperlipidemia will have a documented ICD-9 code for the targeted
             risk factor

          -  Smokers will be identified by a documented ICD-9 code, prescription for a cessation
             medication in the last 12 months or documentation in the chart (e.g. meaningful use
             measure) during the last 12 months (see outcome measures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Shelley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>smoking</keyword>
  <keyword>aspirin</keyword>
  <keyword>chronic care model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

